Finding new treatments & hope through clinical trials in Quebec
Clinical trials are a crucial step in developing new treatments and therapies for sarcoma patients in Quebec. These studies rigorously evaluate the safety and effectiveness of innovative interventions like drugs and vaccines, ensuring they meet the highest standards for sarcoma care. Participating in trials not only benefits current patients but also drives progress towards groundbreaking treatments, providing hope for the future. Explore the ongoing clinical trials conducted by SaRC-Q physicians below to join us in the fight against sarcoma.
Clinical Trials Conducted by SaRC-Q Group
We invite you to explore the ongoing clinical trials conducted by the SaRC-Q group. If you are interested in participating in one of these groundbreaking trials, we encourage you to discuss with your oncologist. To connect with the trial investigator, please do not hesitate to reach out to us at info@sarcq.com.
If you are interested to open or sponsor a clinical trial, please contact us.
Last Updated: August, 2026
| Sarcoma Subtype | Study Name & Description | Phase | Sponsor | Participating Hospitals | Status |
|---|---|---|---|---|---|
| Soft Tissue Sarcoma, Osteosarcoma | Phase 1b/2 Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Previously Treated Unresectable Advanced or Metastatic Sarcomas | I | GlaxoSmithKline Research & Development Limited | MUHC | Active |
| Advanced Cancer | A First in Human, Dose-Escalation Study of TORL-3-600 in Participants with Advanced Cancer | I | TORL | MUHC | Active |
| Advanced Solid Tumors | A Phase 1a/B Open-Label Master Study of Pf-07799544 As A Single-Agent And In Combination With Other Targeted Agents In Participants With Advanced Solid Tumors | I | Pfizer | Jewish General Hospital McGill University Health Centre Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus | Active |
| Leiomyosarcoma, Liposarcoma | Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma | III | EORTC, UVA Health | MUHC | Active |
| Rhabdomyosarcoma | COG-ARST2031 A Randomized Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy With Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance in Patients With High Risk Rhabdomyosarcoma (HR-RMS) | III | Children's Oncology Group | MUHC CHU Sainte-Justine CHUQ | Active, Open for recruitment |
| All tumors | First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies | I | AstraZeneca Clinical Study Information Center | MUHC | Active |
| All tumors | A First in Human Study of TORL-4-500 in Patients With Advanced Cancer (TRIO056) | I | TORL Biotherapeutics | MUHC | Active |
| All tumors | First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors that are Antigen-rich (START-001) | I/II | Marengo Therapeutics, Inc. | MUHC | Active |
| All tumors | Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK06, a 5T4 Antibody Drug Conjugate, in Patients with Unresectable Locally Advanced or Metastatic Cancer | I/II | Salubris Biotherapeutics, Inc. | MUHC | Active |
| All tumors | An Open-label, Multicenter Clinical Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Anti-Cancer Activity of PQ203 in Patients with Advanced Solid Tumor Malignancies | I | ProteinQure Inc. | MUHC | Active |
| Osteosarcoma | A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of GSK5764227 in Participants with Advanced Solid Tumors | I | GSK Research & Development Limited | MUHC | Active |
| GIST | A Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) versus Sunitinib in Participants with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) after Imatinib Therapy (StrateGIST 3). | III | GSK Research & Development Limited | MUHC | Active |
| GIST | Peak A randomized trial of CGT9486+Sunitinib vs. Sunitinib in subjects with gastrointestinal stromal tumors | III | Cogent Biosciences | Maisonneuve-Rosemont Hospital (HMR) | Active, Closed for Recruitment |
| Wild-type Solid Tumors | An Open-Label, Multi-Center Study to Investigate the Safety and Tolerability of SA53, an MDM2 Inhibitor, in Patients with Locally Advanced or Metastatic p53 Wild-type Solid Tumors (ACADIA) | I | PI initiated | MUHC | Active |
| Leiomyosarcoma, Liposarcoma | A Randomized Study of Neoadjuvant Chemotherapy Followed by Surgery versus Surgery Alone for Patients with High Risk Retroperitoneal Sarcoma (STRASS2) | III | CCTG SR.7 | Maisonneuve-Rosemont Hospital (HMR) MUHC | Closed |
| Leiomyosarcoma | ADI-PEG 20 or Placebo Plus Gemcitabine and Docetaxel in Previously Treated Subjects with Leiomyosarcoma (ARGSARC): A Randomized, Double-Blind, Multi-Center Phase 3 Trial. (ARGSARC) | III | Polaris Pharmaceuticals | MUHC | Closed |
| Osteosarcoma | CLIN-60000-461 (CabOSTar), A randomized, open-label study to assess the efficacy, safety, and pharmacokinetics (PK) of maintenance cabozantinib (XL184) plus best supportive care (BSC) versus BSC in children, adolescents and young adults (AYA) with unresectable residual osteosarcoma either at diagnosis or at first relapse after standard treatment. | II | Ipsen Innovation | MUHC | Closed |
| GIST | An International, Randomized, Multicenter, Open-label Study of Ripretinib vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumor (GIST) with KIT Exon 11 and Co-occurring KIT Exons 17 and/or 18 Mutations Who Were Previously Treated with Imatinib (INSIGHT) | III | Deciphera Pharmaceuticals LLC | MUHC | Closed |
| GIST | INTRIGUE A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib | III | Deciphera Pharmaceuticals LLC | Maisonneuve-Rosemont Hospital (HMR) | Closed |
| Advanced Solid Tumors | TAK-676-1002 An Open-Label, Dose Escalation Study to Evaluate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of TAK-676 As A Single Agent And In Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors | I | Takeda | Jewish General Hospital McGill University Health Centre | Closed |
| Chondrosarcoma | A Phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib in participants ≥18 years of age with locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 systemic treatment regimen. (CHONQUER) | III | Servier Bio-Innovation LLC | MUHC | Closed |
| Tenosynovial Giant Cell Tumour | A Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects with Tenosynovial Giant Cell Tumour | III | SynOx Therapeutics | MUHC | Closed |
| Rhabdomyosarcoma | ARST-1431 Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma | III | National Cancer Institute (NCI) | MUHC CHU Sainte-Justine | Closed |
| Tenosynovial Giant Cell Tumor | A Randomized, Double-blind, Placebo-Controlled, Multicenter Study of ABSK021 to Assess the Efficacy and Safety in Patients with Tenosynovial Giant Cell Tumor | III | Abbisko Therapeutics | MUHC | Closed |
| Leiomyosarcoma | SUNRISE-LMS A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS) | II-III | PTC Therapeutics | Maisonneuve-Rosemont Hospital (HMR) | Closed |
| Dedifferentiated Liposarcoma | Brightline-1 A Study to Compare BI 907828 With Doxorubicin in People With Dedifferentiated Liposarcoma | II-III | Boehringer Ingelheim | Maisonneuve-Rosemont Hospital (HMR) | Closed |
| Desmoid Tumors | A Randomized, Double-Blind, Placebo-Controlled Trial of Nirogacestat versus Placebo in Adult Patients with Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF) | III | Spring Works Therapeutics | MUHC | Closed |
| Synovial Sarcoma Myxoid Liposarcoma | IGNYTE-ESO Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors | II | GlaxoSmithKline | Maisonneuve-Rosemont Hospital (HMR) | Closed |
| Synovial Sarcoma Myxoid Liposarcoma | ZENITH-ESO Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors | I | GlaxoSmithKline | Maisonneuve-Rosemont Hospital (HMR) | Closed |
| Tenosynovial Giant Cell Tumor | A Multicenter Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor | I-II | Deciphera Pharmaceuticals LLC | MUHC | Closed |
| Soft Tissue Sarcoma | A randomized controlled trial of Neoadjuvant Pembrolizumab with Radiotherapy and Adjuvant Pembrolizumab in patients with high-risk localized soft tissue sarcoma of the extremity | II | SARC | MUHC | Closed |